GE HealthCare agrees $945 million purchase of SOFIE Biosciences
GE HealthCare has signed an agreement to buy SOFIE Biosciences from Trilantic North America for $945 million in cash. The target is slated to enter GE HealthCare’s Pharmaceutical Diagnostics segment after a first-half 2027 closing, pending regulatory clearance and other conditions. SOFIE is a U.S. producer-for-hire of PET radiopharmaceuticals and is expected to keep supplying its current customers after completion.
Why it matters
GE HealthCare says the purchase would expand its U.S. manufacturing and supply reach for time-sensitive PET products. The company expects the transaction to improve revenue growth, adjusted EBIT margin and adjusted EPS in the first complete year of ownership.
Key facts
- 1GE HealthCare announced the agreement on October 5, 2026. securities.io
- 2SOFIE operates 15 U.S. manufacturing locations with 21 cyclotrons. securities.io
- 3The transaction gives GE HealthCare U.S. rights to FAPI-74, a Phase III PET radiotracer. securities.io
- 4GE HealthCare said SOFIE will continue operating as a manufacturing partner for its existing customers following closing. securities.io
Open questions
- Some reports give 2024 or early 2025 as expected closing dates, conflicting with the company's H1 2027 timetable.
Summary written by AlphAI from 19 of 19 sources. Not investment advice. Figures are as stated by the linked sources.